Concepedia

Author

Donald Richards

Texas OncologyORCID

Also Known As

D A. Richards, D Richards, D. A. Richards, D. Richards, D.A. Richards, DONALD A. RICHARDS, DONALD RICHARDS, Donald A Richards, Donald A. Richards, Donald Anthony Richards

390

Publications

15.9K

Citations

54

H-Index

109

Concepts

All Affiliations

Texas OncologyRocky Mountain Cancer CentersThe US Oncology NetworkThe University of Texas MD Anderson Cancer CenterDana-Farber Cancer Institute
DR

About

Donald Richards is an author at Texas Oncology specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

34

79

8K

2

Health Sciences

20

22

2.4K

3

Engineering

3

3

80

4

Management

1

1

17

5

Biochemistry

1

1

30

Donald Richards

×

135

Publications

15K

Citations

51

H-Index

YearCitations

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang,

The Lancet

2018

1.3K

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky,

The Lancet

2015

1.2K

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set

Eric A. Klein, Donald Richards, Allen Lee Cohn,

Annals of Oncology

2021

872

Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study

Charles S. Fuchs, John L. Marshall, Edith P. Mitchell,

Journal of Clinical Oncology

2007

854

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

Daniel D. Von Hoff, Joseph J. Stephenson, Peter J. Rosen,

Journal of Clinical Oncology

2010

628

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

Stephen E. Jones, Frankie A. Holmes, Joyce O’Shaughnessy,

Journal of Clinical Oncology

2009

584

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen,

The Lancet Oncology

2017

578

Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer

Stephen E. Jones, John K. Erban, Beth Overmoyer,

Journal of Clinical Oncology

2005

546

Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer

Stephen E. Jones, Michael A. Savin, Frankie A. Holmes,

Journal of Clinical Oncology

2006

537

Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology

Nasser H. Hanna, Marcus A. Neubauer, Constantin T. Yiannoutsos,

Journal of Clinical Oncology

2008

492

Page 1